RWReta Anggraeni Widya

Reta Anggraeni Widya

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Reta Anggraeni Widya has a total of 9 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Handling Diabetic patients with septic shock condition, AE-COPD, and HAP pneumonia given fluconazole infusion: A case report

    by Dhimas Aditya Kusuma Bakti, Rani Nur Badriyah, Reta Anggraeni Widya, Jainuri Erik Pratama, Fauna Herawati, Adji Prayitno, Marisca Evalina Gondokesumo

    Chronic obstructive pulmonary disease (COPD) is a disease characterized by abnormalities in ventilation, including disturbances in the airflow channel. In case this patient is 58 years old with a diagnosis of chronic obstructive pulmonary disease, acute exacerbation (COPD AE), Heart Failure (HF), Coronary Artery Disease (CAD), Hypokalemia, Hypoalbumin. When treated in the intensive care unit (ICU) patient experiencing HAP pneumonia and septic condition, with blood sugar at 324, and use insulin later in an empirical patient treated with antifungal Fluconazole infusion, from the drugs used, researchers need to examine whether fluconazole and insulin are used in the therapy of septic conditions with diabetes. After conducting a literature review of the use of fluconazole infusion and insulin in patients with septic condition cases, things This done to prevent the occurrence of death in patients treated in the ICU. Fluconazole and insulin in the treatment of ICU patients with septic conditions have an appropriate level for preventing death.

  • Open Access

    Analysis of ANC Levels after Filgrastim Therapy in Acute Leukemia Children with Neutropenia

    by Reta Anggraeni Widya, Susanto Nugroho, Sri Winarsih, Yulistiani Yulistiani

    Cytotoxic chemotherapy suppresses the hematopoietic system, and the most serious hematologic toxicity is neutropenia. This can decrease a risk of infection that causes delays in treatment and reduction of dose intensity, which reduces therapeutic outcome. Filgrastim is used to increase neutrophils level whose therapeutic effect is unknown. The effectiveness of filgrastim is based on the ANC level pre- and post-therapy. This study aimed to analyze the use of filgrastim on ANC level changes in acute leukemia children with neutropenia, and to analyze the patient that achieve ANC level’s targeted therapy = 1000 cell/mm3. A prospective observational study with a longitudinal design was conducted from June to October 2016. The inclusion criteria of the study were patients who diagnosed acute leukemia with neutropenia and received filgrastim 10 µg/kgBW for 3, 4, 5 days. Patients’ ANC levels were measured before and after filgrastim therapy. This study has been approved its ethical clearance by Dr. Saiful Anwar Hospital, Malang. Data were obtained on the basis of neutropenic episodes, followed by 7 episodes of obtaining filgrastim for 3 days, 1 episode of obtaining filgrastim for 4 days, and 7 episodes of obtaining filgrastim for 5 days. Thus, it consists of 15 episodes. In 3 days, ANC levels increased by 9.5 fold from 381.3 ± 91.8 cell/mm3 to 3984.9 ± 426.8 cell/mm3, but in 5 days, ANC levels decreased by 0.9 fold from 200.9 cell/mm3 ± 98.2 to 189.7 ± 14.2 cell/mm3. Filgrastim was able to increased the ANC levels around nine fold for 3 days of theraphy. There were 53% neutropenia patients who achieved the goal of therapy. Filgrastim therapy with dose 10 µg/kgBW for 3 to 5 days has been able to reach the therapeutic target of 53% in acute leukemia children with neutropenia. The increased levels of ANC maximum was reached on the third day with increased levels of 9.5 fold.